New Products

HAYWARD, Calif. — Impax Labs has settled a patent-infringement suit filed by Purdue Pharma concerning the opioid painkiller OxyContin, Impax said Tuesday.

NOIDA, India — The Food and Drug Administration has approved a generic version of a drug for schizophrenia and bipolar disorder made by Jubilant Life Sciences, the Indian drug maker said.

Jubilant announced the approval of quetiapine fumarate tablets in the 25-mg strength. The drug is a generic version of AstraZeneca's Seroquel.

Various versions of the drug have annual sales of about $59 million, according to IMS Health.

PHILADELPHIA — Sandoz will market an authorized generic version of an attention deficit hyperactivity disorder drug made by Shire under a contract between the two companies, Shire said Monday.

Shire said Sandoz, the generics division of Swiss drug maker Novartis, would market an authorized generic version of Adderall XR (amphetamine; dextroamphetamine).

MINNEAPOLIS — Rememband announced on Monday the launch of the Rememband silicon bracelet on Kickstarter, a crowd-funding website.  

NEW YORK — As the glamour and glitz of the winter season approaches, women are looking for hair accessories to complement their apparel. Enter Karina Hair Accessories.

ST. LOUIS — Cat litter brand Tidy Cats has introduced new LightWeight 24/7 Performance cat litter, which is 50% lighter in weight than traditional scooping cat litter.

A recent survey of cat owners revealed that 61% of owners hate dealing with heavy cat litter; 35% agreed that one of the top challenges with heavy litters is the inability to carry other items at the same time when bringing it into their home.

STAMFORD, Conn. — The Food and Drug Administration has accepted Purdue Pharma's regulatory approval application for a new opioid drug, Purdue said Tuesday.

The drug maker announced the FDA's acceptance of its application for Targiniq (oxycodone hydrochloride; naloxone hydrochloride) controlled-release tablets. The drug combines oxycodone with the opioid agonist nalxone.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration has approved a new tablet form of an antifungal drug made by Merck, the company said Tuesday.

Merck announced the FDA approval of Noxafil (posaconazole) 100-mg delayed release tablets. The company also markets a 40-mg-per-milliliter oral suspension form of the drug. The new tablet formulation is designed to be taken in two 300-mg doses on the first day, followed by a 300-mg dose once per day.